MCID: EXC002
MIFTS: 43

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Exocrine Pancreatic Insufficiency

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 11 53 5 43 14 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:13316
MeSH 43 D010188
NCIt 49 C84316
SNOMED-CT 68 47367009
UMLS 71 C0267963

Summaries for Exocrine Pancreatic Insufficiency

MalaCards based summary: Exocrine Pancreatic Insufficiency is related to shwachman-diamond syndrome 1 and johanson-blizzard syndrome. An important gene associated with Exocrine Pancreatic Insufficiency is SCT (Secretin), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Type II diabetes mellitus. The drugs Glucagon and Dulaglutide have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and bone marrow, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia: 75 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Related Diseases for Exocrine Pancreatic Insufficiency

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 shwachman-diamond syndrome 1 32.1 SBDS ELANE EFL1
2 johanson-blizzard syndrome 32.0 UBR1 SBDS CEL
3 pancreatitis, hereditary 31.5 SPINK1 SCT CFTR CCK
4 cystic fibrosis 31.2 TNF SPINK1 SCT PNLIP ELANE CFTR
5 diarrhea 31.0 TNF SCT CFTR CCK
6 celiac disease 1 30.6 TNF SCT CTLA4 CELA3B CELA1 CCK
7 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 30.4 PDX1 CEL
8 pancreatic steatorrhea 30.4 SCT PNLIP CELA3B CELA1
9 pancreas, annular 30.3 SPINK1 PTF1A
10 alcoholic pancreatitis 30.3 SPINK1 SCT CFTR CCK
11 bowel dysfunction 30.2 TNF CFTR CCK
12 type 2 diabetes mellitus 30.1 TNF SPINK1 SCT PNLIP PDX1 CCKAR
13 alpha-1-antitrypsin deficiency 30.0 TNF ELANE CFTR
14 acute pancreatitis 30.0 TNF SPINK1 SCT PNLIP ELANE CFTR
15 bronchiectasis 30.0 TNF ELANE CFTR
16 gastroesophageal reflux 30.0 TNF ELANE CCKAR CCK
17 gallbladder disease 30.0 CFTR CCKAR CCK
18 primary biliary cholangitis 30.0 TNF SCT CTLA4 CFTR
19 maturity-onset diabetes of the young 29.9 PTF1A PDX1 CFTR CEL
20 pancreatitis 29.9 UBR1 TNF SPINK1 SCT PNLIP ELANE
21 autoimmune pancreatitis 29.7 SPINK1 SCT CFTR CELA3B CELA1
22 diabetes mellitus 29.4 TNF SPINK1 SCT PTF1A PNLIP PDX1
23 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 11.8
24 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 11.4
25 pancreatic agenesis 1 11.2
26 pancreatic agenesis 2 11.2
27 neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1 11.2
28 neutropenia, severe congenital, 8, autosomal dominant 11.2
29 nutritional deficiency disease 10.6
30 overgrowth syndrome 10.6
31 vitamin b12 deficiency 10.5
32 type 1 diabetes mellitus 10.5
33 irritable bowel syndrome 10.4
34 alcohol dependence 10.4
35 pancreatic cancer 10.4
36 rickets 10.4
37 keratomalacia 10.4
38 neutropenia 10.4
39 gastrointestinal system disease 10.4
40 heart defects, congenital, and other congenital anomalies 10.3 PTF1A PDX1
41 alcohol use disorder 10.3
42 dysostosis 10.3
43 hypoglycemia 10.3
44 duodenal obstruction 10.3 SPINK1 CCK
45 functionless pituitary adenoma 10.3 CCKAR CCK
46 gastroduodenal crohn's disease 10.3 TNF CCK
47 chronic orbital inflammation 10.3 TNF CTLA4
48 common bile duct disease 10.2 SPINK1 CELA3B CCK
49 granulomatous hepatitis 10.2 TNF CTLA4
50 pyle disease 10.2

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

GenomeRNAi Phenotypes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 CCK CCKAR CEL CELA1 CELA3B CFTR
2 no effect GR00402-S-2 10.19 CCK CEL CELA1 CELA3B CFTR COX4I1

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 CCK CCKAR CEL CFTR COX4I2 CTLA4
2 liver/biliary system MP:0005370 9.97 CCKAR CEL CFTR CTLA4 PDX1 PNLIP
3 no phenotypic analysis MP:0003012 9.91 CCK CFTR PDX1 PIEZO2 PTF1A SPINK1
4 endocrine/exocrine gland MP:0005379 9.85 CCK CCKAR CFTR CTLA4 PDX1 PTF1A
5 digestive/alimentary MP:0005381 9.7 CCKAR CEL CFTR CTLA4 PDX1 PNLIP
6 respiratory system MP:0005388 9.17 CCKAR CELA1 CFTR COX4I2 CTLA4 PTF1A

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glucagon Approved Phase 2 16941-32-5 16133228 16186314
2
Dulaglutide Approved, Investigational Phase 2 923950-08-7
3
Esomeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6, 119141-88-7 9568614 4594
4
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 2 8002-43-5, 1446756-47-3, 18656-38-7 26197 9547096 6323481
5
Choline Approved, Nutraceutical Phase 2 62-49-7 305
6 Bile Acids and Salts Phase 2
7 Omega 3 Fatty Acid Phase 2
8 Flax Phase 2
9 Soy Bean Phase 2
10 Sunflower Phase 2
11 Insulin, Globin Zinc Phase 2
12
Insulin Phase 2
13 Hypoglycemic Agents Phase 2
14 Glucagon-Like Peptide 1 Phase 2
15 Anti-Ulcer Agents Phase 2
16 Antacids Phase 2
17 Proton Pump Inhibitors Phase 2
18
Phylloquinone Approved, Investigational Phase 1 84-80-0 5284607
19
Menadione Approved, Nutraceutical Phase 1 58-27-5 4055
20 Menaquinone Investigational Phase 1 1182-68-9
21 Vitamins Phase 1
22 Vitamin K Phase 1
23 Trace Elements Phase 1
24 Antifibrinolytic Agents Phase 1
25 Hemostatics Phase 1
26
Naphthoquinone Phase 1
27 Micronutrients Phase 1
28 Coagulants Phase 1
29
Carbamide peroxide Approved 124-43-6
30
Repaglinide Approved, Investigational 135062-02-1 65981
31
Flurbiprofen Approved, Investigational 5104-49-4 3394
32
Acarbose Approved, Investigational 56180-94-0 441184 444254
33
Metformin Approved 1115-70-4, 657-24-9 4091
34
Remifentanil Approved 132875-61-7 60815
35
Diazepam Approved, Illicit, Investigational, Vet_approved 439-14-5 3016
36
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
37
Tannic acid Approved 1401-55-4 16129878 16129778
38
Gastric inhibitory polypeptide Investigational 100040-31-1
39
Sitagliptin Phosphate 654671-77-9
40 HIV Protease Inhibitors
41 Dipeptidyl-Peptidase IV Inhibitors
42
protease inhibitors
43 Pharmaceutical Solutions
44 Cardiac Glycosides
45 Glycoside Hydrolase Inhibitors
46 Incretins
47
bilirubin 635-65-4 5280352
48 Liver Extracts

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
2 A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01100606 Phase 4 EUR-1008 (APT-1008)
3 A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF) Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
4 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
5 An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
6 A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis Completed NCT03924947 Phase 4 Pancrelipase
7 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
8 MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
9 A Phase 4 Study to Assess Symptoms of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon® (Pancrelipase) With an Alternate Source of Active Pharmaceutical Ingredient Recruiting NCT05069597 Phase 4 CREON
10 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Terminated NCT03859869 Phase 4 Pancrelipase;Placebo
11 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency Terminated NCT00744250 Phase 4 Pancrelipase
12 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
13 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
14 A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer Withdrawn NCT04315311 Phase 4 CREON
15 A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
16 A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Unknown status NCT03051490 Phase 3 Liprotamase;porcine PERT
17 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
18 An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449904 Phase 3 Liprotamase
19 A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
20 A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
21 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
22 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
23 A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
24 A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
25 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
26 An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
27 A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo
28 A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
29 A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00400842 Phase 3 SA-001;Placebo
30 A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
31 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
32 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
33 A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy Completed NCT00401076 Phase 3 SA-001
34 A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension Completed NCT00705978 Phase 3 Pancreatin;Placebo
35 A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
36 An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
37 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
38 Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old Completed NCT00880100 Phase 3 Ultrase® MT12
39 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
40 Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects Recruiting NCT03450772 Phase 3 Creon® 25000;Creon® 10000
41 Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency Not yet recruiting NCT04231279 Phase 3 synthetic human secretin
42 An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy Terminated NCT00500084 Phase 3 Liprotamase
43 A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT03746483 Phase 2 MS1819;Porcine PERT
44 An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI). Completed NCT00559052 Phase 2 VIOKASE 16
45 OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules Completed NCT04375878 Phase 2 MS1819;Porcine PERT
46 A Multicenter, Open-label Phase 2 Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs, to Investigate the Efficacy and Safety of This Combination for the Compensation of Severe Exocrine Pancreatic Insufficiency in CF Patients Not Fully Compensated With Only PPEs Completed NCT04302662 Phase 2 MS1819-SD
47 A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo
48 A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
49 A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy Completed NCT03481803 Phase 2 MS1819-SD
50 An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency Completed NCT00743483 Phase 2 rhBSSL

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Genetic Tests for Exocrine Pancreatic Insufficiency

Anatomical Context for Exocrine Pancreatic Insufficiency

Organs/tissues related to Exocrine Pancreatic Insufficiency:

MalaCards : Pancreas, Liver, Bone Marrow, Small Intestine, Bone, Kidney, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Affected by disease, potential therapeutic candidate

Publications for Exocrine Pancreatic Insufficiency

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 1348)
# Title Authors PMID Year
1
13C-labeled mixed triglyceride breath test (13C MTG-BT) in healthy children and children with cystic fibrosis (CF) under pancreatic enzyme replacement therapy (PERT): a pilot study. 53 62
18817766 2008
2
Exocrine pancreatic insufficiency in the Eurasian dog breed--inheritance and exclusion of two candidate genes. 53 62
17302791 2007
3
Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? 53 62
17269988 2007
4
Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests. 53 62
17016144 2006
5
Homozygous (TG)11 allele in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has a protective role against bicarbonate decrease in pure pancreatic juice among Japanese male alcoholics. 53 62
15645646 2004
6
[New fecal markers: recent developments and perspectives]. 53 62
15550893 2004
7
Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. 53 62
12604981 2003
8
Faecal elastase 1 concentration is a marker of duodenal enteropathy. 53 62
11806885 2002
9
[Maldigestion during chronic pancreatitis]. 53 62
11458612 2001
10
Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis. 53 62
10192202 1999
11
Comparative clinical evaluation of the 13C-mixed triglyceride breath test as an indirect pancreatic function test. 53 62
9548629 1998
12
13C-starch breath test--comparative clinical evaluation of an indirect pancreatic function test. 53 62
9106982 1997
13
Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. 53 62
8981511 1997
14
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. 53 62
8595714 1996
15
Maldigestion after total gastrectomy is associated with pancreatic insufficiency. 53 62
8607504 1996
16
[Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function]. 53 62
8761139 1996
17
Lack of accuracy of plasma alpha-amino nitrogen profiles as an indicator of exocrine pancreatic function both after continuous and bolus stimulation of the pancreas with secretin and cholecystokinin-pancreozymin. 53 62
7871858 1994
18
Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. 53 62
8194711 1994
19
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. 53 62
1636270 1992
20
Fecal isoamylase activity in patients with pancreatic diseases. 53 62
1704633 1991
21
Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. 62
36110921 2022
22
Impact of recurrent acute pancreatitis on the natural history and progression to chronic pancreatitis. 62
36150985 2022
23
Adar1 deletion causes degeneration of the exocrine pancreas via Mavs-dependent interferon signaling. 62
36458554 2022
24
Overcoming the Pitfalls of Next-Generation Sequencing-Based Molecular Diagnosis of Shwachman-Diamond Syndrome. 62
36162759 2022
25
Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria. 62
35704255 2022
26
Undiagnosed Exocrine Pancreatic Insufficiency in Diarrhea-Predominant Irritable Bowel Syndrome. 62
35705731 2022
27
The clinical and laboratory impact of reporting faecal elastase-1 in watery stool samples. 62
36424839 2022
28
In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model. 62
36442722 2022
29
Community Perspective on Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. 62
36070542 2022
30
Assessment of Exocrine Pancreatic Function Following Bariatric/Metabolic Surgery: a Prospective Cohort Study. 62
36437437 2022
31
Minimally invasive versus open central pancreatectomy: Systematic review and meta-analysis. 62
35987787 2022
32
Exocrine pancreatic insufficiency after bariatric surgery. 62
35931645 2022
33
Risk factors for exocrine pancreatic insufficiency after pancreatic surgery: a systematic review and meta-analysis. 62
36384688 2022
34
Analysis of INSPPIRE-2 Cohort: Risk Factors and Disease Burden in Children With Acute Recurrent or Chronic Pancreatitis. 62
35976273 2022
35
Regional gastrointestinal transit times in patients with chronic pancreatitis. 62
36253998 2022
36
Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Other Gastrointestinal Pathology in the Cystic Fibrosis Patient. 62
36209752 2022
37
Responses of Ileal and Fecal Microbiota to Withdrawal of Pancreatic Enzyme Replacement Therapy in a Porcine Model of Exocrine Pancreatic Insufficiency. 62
36233002 2022
38
Pancreas-preserving total duodenectomy for advanced duodenal polyposis in patients with familial adenomatous polyposis: short and long-term outcomes. 62
35568653 2022
39
Experience in the resection of the uncinate process of the pancreas: indications and results. literature review. 62
36283601 2022
40
Long-term changes of pancreatic function in patients with complicated walled-off necrosis. 62
35546222 2022
41
Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. 62
35717430 2022
42
Fetal Description of the Pancreatic Agenesis and Holoprosencephaly Syndrome Associated to a Specific CNOT1 Variant. 62
35481434 2022
43
Effect of oral or injectable supplementation with cobalamin in dogs with hypocobalaminemia caused by chronic enteropathy or exocrine pancreatic insufficiency. 62
36054643 2022
44
[Clinical phenotypes and genotypic spectrum of cystic fibrosis with pancreatic insufficiency in children]. 62
36038301 2022
45
Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification. 62
36161510 2022
46
CFTR regulates brown adipocyte thermogenesis via the cAMP/PKA signaling pathway. 62
36088207 2022
47
Ptf1a function and transcriptional cis-regulation, a cornerstone in vertebrate pancreas development. 62
34125483 2022
48
Exocrine pancreatic insufficiency and graft-versus-host disease. 62
36148693 2022
49
Morphological and functional recovery following acute and acute recurrent pancreatitis in children: A prospective sequential 2-point evaluation. 62
35717306 2022
50
Emerging medicines to improve the basic defect in cystic fibrosis. 62
35731915 2022

Variations for Exocrine Pancreatic Insufficiency

ClinVar genetic disease variations for Exocrine Pancreatic Insufficiency:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIEZO2 NM_001378183.1(PIEZO2):c.64+1G>A SNV Likely Pathogenic
1683711 GRCh37: 18:11148523-11148523
GRCh38: 18:11148524-11148524
2 CTR9 NM_014633.5(CTR9):c.85G>A (p.Glu29Lys) SNV Uncertain Significance
1707508 GRCh37: 11:10774258-10774258
GRCh38: 11:10752711-10752711

Expression for Exocrine Pancreatic Insufficiency

Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.

Pathways for Exocrine Pancreatic Insufficiency

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 PTF1A PDX1 CFTR
2 10.66 TNF PDX1
3 10.37 SBDS EFL1 COX4I2
5 9.91 SCT CCK

GO Terms for Exocrine Pancreatic Insufficiency

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 9.8 PDX1 COX4I2 COX4I1
2 intestinal cholesterol absorption GO:0030299 9.71 PNLIP CEL
3 pancreatic juice secretion GO:0030157 9.67 SCT CEL
4 cytosolic ribosome assembly GO:0042256 9.56 SBDS EFL1
5 response to nutrient levels GO:0031667 9.5 TNF SPINK1 SCT PDX1
6 positive regulation of pancreatic juice secretion GO:0090187 9.46 SPINK1 SCT
7 exocrine pancreas development GO:0031017 9.1 PTF1A PDX1 CELA1

Sources for Exocrine Pancreatic Insufficiency

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....